Agomelatine: first melatonergic agonist for depression
Authors
Abstract
Agomelatine (Valdoxan) is a new antidepressant with unique melatonin receptor agonist activity. In our New products review, Professor Bill Deakin presents the clinical data relating to its efficacy and safety, and describes its place in the treatment of depression. Copyright © 2009 Wiley Interface Ltd.
Digital Object Identifier (DOI)
10.1002/psb.554 About DOI
Login/Logout
Journal Menu
- Home
- News
- Current Issue
- Archive Issues
- Learning Central
- Ask Prescriber
- Prescriber Blog
- Forthcoming Events
- Supplements
- Wiley Job Network
Advertising and Sponsorship
Other Journals
